查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1344508

糖尿病足部潰傷治療市場:各產品類型，各終端用戶:全球機會分析與產業預測，2023-2032年

Diabetic Foot Ulcer Treatment Market By Product, By Type, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 296 Pages | 商品交期: 2-3個工作天內

價格

2022 年糖尿病足潰瘍治療市場價值為 44 億美元，預計到 2032 年將達到 74 億美元，複合年增長率為2023年至2032年為5.4%。

糖尿病足潰瘍是糖尿病常見且嚴重的併發症。糖尿病足潰瘍是糖尿病患者足部發生的開放性潰瘍或傷口。糖尿病足潰瘍是由多種與糖尿病相關的因素造成的，包括血液循環不良、神經病變和免疫功能下降。如果不及時治療，糖尿病足潰瘍可能會變成慢性，並促使嚴重的併發症，如感染、壞疽，甚至截肢。因此，正確管理和治療糖尿病足潰瘍對於預防這些併發症和促進傷口癒合至關重要。

Diabetic Foot Ulcer Treatment Market-IMG1

推動糖尿病足潰瘍治療發展的主要因素是患有糖尿病足潰瘍的人數不斷增加、研發活動的增加以及對適當糖尿病足護理的意識的提高。久坐的生活、不健康的飲食和日益肥胖等因素加劇了全球糖尿病發生率的上升。此外，高血糖水平的延遲會促使周圍神經病變，這種疾病會損害腳趾神經並減弱感覺。此外，血液循環不良（稱為週邊動脈疾病）會進一步損害腳部傷口的癒合。這些因素與不斷發展的糖尿病族群結合，促使糖尿病足潰瘍的發生頻率增加。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
    • 影響要素
    • 主要的投資機會
  • 波特的五力分析
  • 市場動態
    • 促進因素
      • 糖尿病足部潰傷的增加
      • 傷口護理管理上技術的進步
      • 糖尿病足部潰傷治療的新產品銷售的增加
    • 阻礙因素
      • 創傷護理產品的製造相關嚴格法規
    • 機會
      • 新興市場的成長機會
  • COVID-19對市場的影響分析

第4章 糖尿病足部潰傷治療藥市場:各產品

  • 概要
  • 傷口敷料
  • 創傷護理器具
  • 生技藥品
  • 其他

第5章 糖尿病足部潰傷治療市場:各類型

  • 概要
  • 神經病變性潰瘍
  • 缺血性潰瘍
  • 神經缺血性潰瘍

第6章 糖尿病足部潰傷治療市場:各終端用戶

  • 概要
  • 醫院
  • 居家醫療
  • 其他

第7章 糖尿病足部潰傷治療市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 南美·中東·非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭情形

  • 簡介
  • 主要成功策略
  • 主要10企業的產品製圖
  • 競爭儀表板
  • 競爭熱圖
  • 主要企業的定位，2022年

第9章 企業簡介

  • ConvaTec Group plc
  • 3M Company
  • Cardinal Health Inc.
  • ORGANOGENESIS HOLDINGS INC.
  • Smith and Nephew plc.
  • B. Braun SE
  • Coloplast
  • Integra LifeSciences Holdings Corporation
  • Molnlycke Health Care AB
  • Essity Aktiebolag AB
Product Code: A110954

According to a new report published by Allied Market Research, titled, "Diabetic Foot Ulcer Treatment Market," The diabetic foot ulcer treatment market was valued at $4.4 billion in 2022, and is estimated to reach $7.4 billion by 2032, growing at a CAGR of 5.4% from 2023 to 2032. Diabetic foot ulcers are a common and serious complication of diabetes mellitus. They are open sores or wounds that typically develop on the feet of individuals with diabetes. Diabetic foot ulcers are a result of various factors, including poor circulation, nerve damage (neuropathy), and impaired immune function, which are all associated with diabetes. If left untreated, diabetic foot ulcer can become chronic, leading to severe complications such as infection, gangrene, and even amputation. Thus, proper management and treatment of diabetic foot ulcers are crucial to prevent these complications and promote wound healing.

Diabetic Foot Ulcer Treatment Market - IMG1

The major factors driving the development of the diabetic foot ulcer treatments are increasing number of individuals suffering from diabetic foot ulcers, rise in R & D exercises, and surge in awareness about proper diabetic foot care. The predominance of diabetes is on the rise across the globe, fueled through factors which include sedentary life, unhealthy diets, and growing obesity. Further, delayed periods of high blood sugar level can result in peripheral neuropathy, a condition that harms the nerves in the toes and diminishes sensation. In addition, poor blood circulation, known as peripheral arterial disease, advance impairs wound healing within the feet. These components, combined with the developing diabetic populace, contribute to an expanded frequency of diabetic foot ulcers. For instance, as per, Centers for Disease Control and Prevention (CDC), 2022, almost 12% individuals with diabetes develop diabetic foot ulcers in U.S. Thus, increasing number of individuals suffering from diabetic foot ulcer has driven the request for compelling treatment options and thereby, propelling the development of the diabetic foot ulcer treatment market.

In addition, researchers and medical experts are actively involved in studying the pathophysiology of diabetic foot ulcers, exploring new treatment modalities and improving existing healing procedures. The use of advanced technology has caused the improvement of modern wound care products, bioengineered pores and skin substitutes and off-loading devices. These improvements aim to enhance wound healing, protect infections, and offer better management options for diabetic foot ulcers. Further, there are ongoing studies in field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing. The growing funding in research and development activities by pharmaceutical organizations, instructional institutions and healthcare companies has expanded the invention of novel therapeutic strategies, fueling the growth of the market.

Furthermore, surge in awareness about proper diabetic foot care has contributed to the growth of the diabetic foot ulcer treatment market. Healthcare organizations, diabetes associations, and healthcare professionals had been actively raising focus about the importance of foot care in individuals with diabetes. Diabetic foot ulcers can be averted or minimized through regular foot examinations, right shoes, foot hygiene, and early detection of foot ulcers. Furthermore, education campaigns and initiatives aimed at improving foot care practices have led to increased patient awareness and engagement. As individuals become more aware about the risks and consequences of diabetic foot ulcers, they are more anticipated to seek timely medical attention and adhere to preventive measures. This heightened awareness has not only improved patient outcomes but has also driven the demand for diabetic foot ulcer treatment options.

The global diabetic foot ulcer treatment market is segmented into product, type, end user, and region. On the basis of product, the market is categorized into wound care dressings, wound care devices, biologics and others. The wound care devices segment is further categorized into negative pressure wound therapy and others. Based on type, it is categorized into neuropathic ulcers, ischemic ulcers and neuroischemic ulcers. As per end user, it is segregated into hospitals, homecare settings, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global diabetic foot ulcer treatment market are ConvaTec Group plc, 3M Company, Cardinal Health Inc., Organogenesis Holdings Inc., Smith and Nephew plc., B. Braun SE, Coloplast, Integra LifeSciences Holdings Corporation, Molnlycke Health Care AB, and Essity Aktiebolag AB. The key players have adopted strategies such as acquisition, contract, product launch, and product approval to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic foot ulcer treatment market analysis from 2022 to 2032 to identify the prevailing diabetic foot ulcer treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the diabetic foot ulcer treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global diabetic foot ulcer treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Wound care dressings
  • Wound care devices
    • Type
    • Negative pressure wound therapy
    • Others
  • Biologics
  • Others

By Type

  • Neuropathic ulcers
  • Ischemic ulcers
  • Neuroischemic ulcers

By End user

  • Hospitals
  • Homecare settings
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • 3M Company
    • B. Braun SE
    • Cardinal Health Inc.
    • Coloplast
    • ConvaTec Group plc
    • Essity Aktiebolag AB
    • Integra LifeSciences Holdings Corporation
    • Molnlycke Health Care AB
    • ORGANOGENESIS HOLDINGS INC.
    • Smith and Nephew plc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. High bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of diabetic foot ulcer
      • 3.4.1.2. Technological advancements in wound care management
      • 3.4.1.3. Rise in new product launches for diabetic foot ulcer treatment
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulations for manufacturing of wound care products
    • 3.4.3. Opportunities
      • 3.4.3.1. Growing opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Wound care dressings
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Wound care devices
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Wound care devices Diabetic Foot Ulcer Treatment Market by Type
  • 4.4. Biologics
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Neuropathic ulcers
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Ischemic ulcers
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Neuroischemic ulcers
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Homecare settings
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: DIABETIC FOOT ULCER TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Product
    • 7.2.3. Market size and forecast, by Type
    • 7.2.4. Market size and forecast, by End user
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Product
      • 7.2.5.1.3. Market size and forecast, by Type
      • 7.2.5.1.4. Market size and forecast, by End user
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Product
      • 7.2.5.2.3. Market size and forecast, by Type
      • 7.2.5.2.4. Market size and forecast, by End user
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Product
      • 7.2.5.3.3. Market size and forecast, by Type
      • 7.2.5.3.4. Market size and forecast, by End user
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Product
    • 7.3.3. Market size and forecast, by Type
    • 7.3.4. Market size and forecast, by End user
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Product
      • 7.3.5.1.3. Market size and forecast, by Type
      • 7.3.5.1.4. Market size and forecast, by End user
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Product
      • 7.3.5.2.3. Market size and forecast, by Type
      • 7.3.5.2.4. Market size and forecast, by End user
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Product
      • 7.3.5.3.3. Market size and forecast, by Type
      • 7.3.5.3.4. Market size and forecast, by End user
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Product
      • 7.3.5.4.3. Market size and forecast, by Type
      • 7.3.5.4.4. Market size and forecast, by End user
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Product
      • 7.3.5.5.3. Market size and forecast, by Type
      • 7.3.5.5.4. Market size and forecast, by End user
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Product
      • 7.3.5.6.3. Market size and forecast, by Type
      • 7.3.5.6.4. Market size and forecast, by End user
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Product
    • 7.4.3. Market size and forecast, by Type
    • 7.4.4. Market size and forecast, by End user
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Product
      • 7.4.5.1.3. Market size and forecast, by Type
      • 7.4.5.1.4. Market size and forecast, by End user
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Product
      • 7.4.5.2.3. Market size and forecast, by Type
      • 7.4.5.2.4. Market size and forecast, by End user
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Product
      • 7.4.5.3.3. Market size and forecast, by Type
      • 7.4.5.3.4. Market size and forecast, by End user
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Product
      • 7.4.5.4.3. Market size and forecast, by Type
      • 7.4.5.4.4. Market size and forecast, by End user
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Product
      • 7.4.5.5.3. Market size and forecast, by Type
      • 7.4.5.5.4. Market size and forecast, by End user
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Product
      • 7.4.5.6.3. Market size and forecast, by Type
      • 7.4.5.6.4. Market size and forecast, by End user
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Product
    • 7.5.3. Market size and forecast, by Type
    • 7.5.4. Market size and forecast, by End user
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Product
      • 7.5.5.1.3. Market size and forecast, by Type
      • 7.5.5.1.4. Market size and forecast, by End user
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Product
      • 7.5.5.2.3. Market size and forecast, by Type
      • 7.5.5.2.4. Market size and forecast, by End user
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Product
      • 7.5.5.3.3. Market size and forecast, by Type
      • 7.5.5.3.4. Market size and forecast, by End user
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Product
      • 7.5.5.4.3. Market size and forecast, by Type
      • 7.5.5.4.4. Market size and forecast, by End user

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. ConvaTec Group plc
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. 3M Company
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Cardinal Health Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. ORGANOGENESIS HOLDINGS INC.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Smith and Nephew plc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. B. Braun SE
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Coloplast
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Integra LifeSciences Holdings Corporation
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Molnlycke Health Care AB
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Essity Aktiebolag AB
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 02. DIABETIC FOOT ULCER TREATMENT MARKET FOR WOUND CARE DRESSINGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. DIABETIC FOOT ULCER TREATMENT MARKET FOR WOUND CARE DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL WOUND CARE DEVICES DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 05. DIABETIC FOOT ULCER TREATMENT MARKET FOR BIOLOGICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. DIABETIC FOOT ULCER TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 08. DIABETIC FOOT ULCER TREATMENT MARKET FOR NEUROPATHIC ULCERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. DIABETIC FOOT ULCER TREATMENT MARKET FOR ISCHEMIC ULCERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. DIABETIC FOOT ULCER TREATMENT MARKET FOR NEUROISCHEMIC ULCERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. DIABETIC FOOT ULCER TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. DIABETIC FOOT ULCER TREATMENT MARKET FOR HOMECARE SETTINGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. DIABETIC FOOT ULCER TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. DIABETIC FOOT ULCER TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA DIABETIC FOOT ULCER TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. U.S. DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. CANADA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 24. CANADA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. UK DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. UK DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. UK DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. ITALY DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. ITALY DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. ITALY DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. CHINA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. CHINA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. INDIA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. INDIA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. CONVATEC GROUP PLC: KEY EXECUTIVES
  • TABLE 90. CONVATEC GROUP PLC: COMPANY SNAPSHOT
  • TABLE 91. CONVATEC GROUP PLC: PRODUCT SEGMENTS
  • TABLE 92. CONVATEC GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 93. CONVATEC GROUP PLC: KEY STRATERGIES
  • TABLE 94. 3M COMPANY: KEY EXECUTIVES
  • TABLE 95. 3M COMPANY: COMPANY SNAPSHOT
  • TABLE 96. 3M COMPANY: PRODUCT SEGMENTS
  • TABLE 97. 3M COMPANY: PRODUCT PORTFOLIO
  • TABLE 98. CARDINAL HEALTH INC.: KEY EXECUTIVES
  • TABLE 99. CARDINAL HEALTH INC.: COMPANY SNAPSHOT
  • TABLE 100. CARDINAL HEALTH INC.: PRODUCT SEGMENTS
  • TABLE 101. CARDINAL HEALTH INC.: PRODUCT PORTFOLIO
  • TABLE 102. CARDINAL HEALTH INC.: KEY STRATERGIES
  • TABLE 103. ORGANOGENESIS HOLDINGS INC.: KEY EXECUTIVES
  • TABLE 104. ORGANOGENESIS HOLDINGS INC.: COMPANY SNAPSHOT
  • TABLE 105. ORGANOGENESIS HOLDINGS INC.: PRODUCT SEGMENTS
  • TABLE 106. ORGANOGENESIS HOLDINGS INC.: PRODUCT PORTFOLIO
  • TABLE 107. ORGANOGENESIS HOLDINGS INC.: KEY STRATERGIES
  • TABLE 108. SMITH AND NEPHEW PLC.: KEY EXECUTIVES
  • TABLE 109. SMITH AND NEPHEW PLC.: COMPANY SNAPSHOT
  • TABLE 110. SMITH AND NEPHEW PLC.: PRODUCT SEGMENTS
  • TABLE 111. SMITH AND NEPHEW PLC.: PRODUCT PORTFOLIO
  • TABLE 112. SMITH AND NEPHEW PLC.: KEY STRATERGIES
  • TABLE 113. B. BRAUN SE: KEY EXECUTIVES
  • TABLE 114. B. BRAUN SE: COMPANY SNAPSHOT
  • TABLE 115. B. BRAUN SE: PRODUCT SEGMENTS
  • TABLE 116. B. BRAUN SE: PRODUCT PORTFOLIO
  • TABLE 117. COLOPLAST: KEY EXECUTIVES
  • TABLE 118. COLOPLAST: COMPANY SNAPSHOT
  • TABLE 119. COLOPLAST: PRODUCT SEGMENTS
  • TABLE 120. COLOPLAST: PRODUCT PORTFOLIO
  • TABLE 121. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 122. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 123. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT SEGMENTS
  • TABLE 124. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 125. MOLNLYCKE HEALTH CARE AB: KEY EXECUTIVES
  • TABLE 126. MOLNLYCKE HEALTH CARE AB: COMPANY SNAPSHOT
  • TABLE 127. MOLNLYCKE HEALTH CARE AB: PRODUCT SEGMENTS
  • TABLE 128. MOLNLYCKE HEALTH CARE AB: PRODUCT PORTFOLIO
  • TABLE 129. ESSITY AKTIEBOLAG AB: KEY EXECUTIVES
  • TABLE 130. ESSITY AKTIEBOLAG AB: COMPANY SNAPSHOT
  • TABLE 131. ESSITY AKTIEBOLAG AB: PRODUCT SEGMENTS
  • TABLE 132. ESSITY AKTIEBOLAG AB: PRODUCT PORTFOLIO
  • TABLE 133. ESSITY AKTIEBOLAG AB: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN DIABETIC FOOT ULCER TREATMENT MARKET (2023-2032)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALDIABETIC FOOT ULCER TREATMENT MARKET
  • FIGURE 09. DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR WOUND CARE DRESSINGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR WOUND CARE DEVICES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR BIOLOGICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR NEUROPATHIC ULCERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR ISCHEMIC ULCERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR NEUROISCHEMIC ULCERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR HOMECARE SETTINGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. DIABETIC FOOT ULCER TREATMENT MARKET BY REGION, 2022
  • FIGURE 23. U.S. DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. JAPAN DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SAUDI ARABIA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH AFRICA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: DIABETIC FOOT ULCER TREATMENT MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2022
  • FIGURE 49. CONVATEC GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. CONVATEC GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. CONVATEC GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. 3M COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. 3M COMPANY: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 54. 3M COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. 3M COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. CARDINAL HEALTH INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. CARDINAL HEALTH INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. CARDINAL HEALTH INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. ORGANOGENESIS HOLDINGS INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. SMITH AND NEPHEW PLC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. SMITH AND NEPHEW PLC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. SMITH AND NEPHEW PLC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. B. BRAUN SE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. B. BRAUN SE: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. B. BRAUN SE: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. COLOPLAST: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. COLOPLAST: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. COLOPLAST: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 70. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. MOLNLYCKE HEALTH CARE AB: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 73. MOLNLYCKE HEALTH CARE AB: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 74. MOLNLYCKE HEALTH CARE AB: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 75. ESSITY AKTIEBOLAG AB: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 76. ESSITY AKTIEBOLAG AB: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 77. ESSITY AKTIEBOLAG AB: REVENUE SHARE BY REGION, 2022 (%)